On 21 July 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Genvoya. The marketing authorisation holder for this medicinal product is Gilead Sciences Ireland UC.
Genvoya is indicated for the treatment of human immunodeficiency virus 1 (HIV 1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in adults and paediatric patients aged from 2 years and with body weight at least 14 kg.
as follows: In adults and adolescents paediatric patients aged from 12 years and with body weight at least 35 kg In children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.
The CHMP also recommended the addition of a new strength as follows: 90 mg/90 mg/120 mg/6 mg film‑coated tablets.
Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.
1 New text in bold, removed text as strikethrough.
|Agency product number||
|International non-proprietary name (INN) or common name||
|Date opinion adopted||
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 September 201525/09/2015